Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Change in Cash (2018 - 2025)

Historic Change in Cash for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to -$428559.0.

  • Regenerative Medical Technology's Change in Cash fell 29539.1% to -$428559.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $349268.0, marking a year-over-year increase of 21357.79%. This contributed to the annual value of $635280.0 for FY2024, which is 15699.39% up from last year.
  • According to the latest figures from Q3 2025, Regenerative Medical Technology's Change in Cash is -$428559.0, which was down 29539.1% from $391325.0 recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's Change in Cash registered a high of $9.7 million during Q2 2021, and its lowest value of -$7.8 million during Q4 2021.
  • Moreover, its 5-year median value for Change in Cash was -$8561.0 (2023), whereas its average is $60166.4.
  • Examining YoY changes over the last 5 years, Regenerative Medical Technology's Change in Cash showed a top increase of 356816801.47% in 2021 and a maximum decrease of 4565457.23% in 2021.
  • Quarter analysis of 5 years shows Regenerative Medical Technology's Change in Cash stood at -$7.8 million in 2021, then surged by 98.39% to -$124451.0 in 2022, then plummeted by 392.89% to -$613401.0 in 2023, then surged by 153.7% to $329393.0 in 2024, then tumbled by 230.11% to -$428559.0 in 2025.
  • Its last three reported values are -$428559.0 in Q3 2025, $391325.0 for Q2 2025, and $57109.0 during Q1 2025.